FQ1-2023Y:
-
Guidance: 20-25% topline growth expected for the 2023FYE. Punjab PPP project saw some delays due to changes in government and approvals but should be functional by the end of September.
-
Centers take 6-9 months to ramp up and functionalize fully with higher footfalls.
-
Punjab (100) and the new Maharashtra+Delhi+Tripura+Rajasthan-R&D (100Cr, Maharastra project is expected to commercialize in the next 9-12 months, and others in the next couple of months) contract has a potential of 200+CR. of revenue.
-
We are also bidding for a massive, state-wise Rajasthan project with a 200cr+ potential.
-
We had high volume growth in test count, but the realization was less as we renewed the Assam contract with competitive pricing due to the ease of doing business, and all facilities are already in place.
-
We have 70% contracts where the pay model is through govt and 30% (like Punjab) where we directly collect cash from patients.
-
2024FY guidance of 2x revenue and 3x profits is intact but will be reviewed in the next quarter.
-
IT raid is under investigation, and they falsified the media reports. The financials shown in those reports are also not legit.
Disc. Invested. (Apologies if I am missing anything, it is my first post since I joined this community!)
Subscribe To Our Free Newsletter |